In the BioHarmony Drug Report Database
Clidinium
Quarzan, Rolufta, Rolufta Ellipta (clidinium) is a small molecule pharmaceutical. Clidinium was first approved as Quarzan on 1982-01-01. It is used to treat inflammatory bowel diseases and peptic ulcer in the USA. It has been approved in Europe to treat chronic obstructive pulmonary disease. The pharmaceutical is active against muscarinic acetylcholine receptor M3. In addition, it is known to target muscarinic acetylcholine receptor M2.
Trade Name
|
Rolufta, Rolufta Ellipta |
|---|---|
Common Name
|
clidinium |
ChEMBL ID
|
CHEMBL620 |
Indication
|
chronic obstructive pulmonary disease, inflammatory bowel diseases, peptic ulcer |
Drug Class
|
Quaternary ammonium derivatives |
Image (chem structure or protein)